Fidson Healthcare Plc, MeCure Industries Plc, and Neimeth International Pharmaceuticals Plc, Nigeria’s top listed pharmaceutical exporters, saw their profit margins squeezed by a sharp rise in production costs despite a surge in demand that lifted revenues by as much as 85 percent in the first quarter of 2025.
The three firms reported double‑digit sales growth year‑on‑year. Fidson led the pack with revenue jumping to N35.02 billion from N18.88 billion in Q1 2024. MeCure followed with N13.29 billion, up from N8.08 billion, while Neimeth posted N1.21 billion, nearly doubling the N648.3 million it recorded in the same period last year. This performance reflects strong demand for healthcare products both domestically and across African markets.
Read also: Pharmaceuticals incur FX losses on naira depreciation
